The immunoglobulin A (IgA) vasculitis market size has grown strongly in recent years. It will grow from $1.53 billion in 2024 to $1.63 billion in 2025 at a compound annual growth rate (CAGR) of 6.5%. The growth during the historic period can be attributed to increasing awareness of IgA vasculitis, a rising incidence of autoimmune diseases, greater use of immunosuppressive therapies, increased research funding for rare diseases, and growing adoption of targeted treatment options.
The immunoglobulin A (IgA) vasculitis market size is expected to see strong growth in the next few years. It will grow to $2.08 billion in 2029 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to the increasing use of advanced biomarkers, rising incidence of comorbid conditions, a growing number of clinical trials, heightened interest in biologic therapies, and expanding demand for minimally invasive treatment options. Major trends include the integration of precision medicine, innovations in immunosuppressive therapies, development of disease-modifying treatments, advancements in biomarkers for early diagnosis, and the incorporation of artificial intelligence in treatment planning.
The rising incidence of autoimmune diseases is expected to drive the growth of the immunoglobulin A (IgA) vasculitis market. Autoimmune diseases occur when the immune system mistakenly attacks the body’s own healthy cells, tissues, or organs instead of defending against infections. The increasing prevalence of these disorders is largely attributed to greater exposure to environmental pollutants, which can disrupt immune regulation and trigger abnormal immune responses. IgA vasculitis plays a role in autoimmune diseases by causing inflammation in small blood vessels, providing insights that may aid in understanding and treating various autoimmune conditions. For example, in November 2024, data from Versorgungsatlas.de, a Germany-based organization, reported that out of 73,241,305 insured individuals in 2022, 6,304,340 were diagnosed with at least one autoimmune disease, corresponding to a raw prevalence rate of 8.61%. Therefore, this rising incidence is propelling the growth of the IgA vasculitis market.
The rising focus on targeted therapies is expected to drive the growth of the immunoglobulin A (IgA) vasculitis market. Targeted therapies are treatments designed to specifically inhibit molecular abnormalities involved in diseases, thereby improving treatment precision and minimizing damage to healthy cells. This growing emphasis on targeted therapies is largely fueled by advancements in precision medicine, which tailors treatments based on an individual’s genetic profile for greater effectiveness. In IgA vasculitis, targeted therapies focus on specific immune pathways, reducing systemic side effects, lowering inflammation, and preventing organ damage - ultimately enhancing patient outcomes and quality of life. For example, in December 2024, the American Society of Gene and Cell Therapy (ASGCT) reported that the FDA approved six gene therapy products in 2023, up from five approvals in 2022, reflecting increased innovation in targeted treatments. Therefore, this rising focus on targeted therapies is propelling the immunoglobulin A vasculitis market forward.
Leading companies in the immunoglobulin A (IgA) vasculitis market are concentrating on creating innovative treatments, including targeted biologics and immunomodulators, aimed at lowering inflammation and preventing kidney-related complications. These advanced therapies work by modulating specific immune pathways to decrease inflammation and protect against immune-driven damage in IgA vasculitis. For example, in April 2025, Novartis AG, a pharmaceutical firm based in Switzerland, obtained approval from the U.S. Food and Drug Administration (FDA) for Vanrafia (atrasentan) to treat primary immunoglobulin A nephropathy (IgAN). Vanrafia is a selective endothelin A receptor antagonist taken orally once daily, intended to reduce proteinuria in adults with primary IgAN who face a high risk of rapid disease progression. It can be added to current supportive care plans without requiring a risk evaluation and mitigation strategy (REMS).
Major players in the immunoglobulin A (IgA) vasculitis market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Novartis AG, Takeda Pharmaceutical Company Limited, Amgen Inc., Indraprastha Medical Corporation Limited, Intas Pharmaceuticals Ltd, Mayo Clinic, Biogen Inc., Chugai Pharmaceutical Co. Ltd., The Cleveland Clinic Foundation, Zydus Lifesciences Limited, CSL Behring, Artemis Medicare Services Limited, Biocad Biotechnology Company, Biotest AG, Kauvery Hospitals Private Limited, Sheikh Shakhbout Medical City, and Reliance Life Sciences Pvt. Ltd.
North America was the largest region in the immunoglobulin A (IgA) vasculitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in immunoglobulin A (IgA) vasculitis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the immunoglobulin A (IgA) vasculitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Immunoglobulin A (IgA) vasculitis is an autoimmune disorder marked by inflammation of small blood vessels caused by deposits of IgA antibodies. It primarily affects the skin, joints, kidneys, and gastrointestinal tract, manifesting as purplish rashes, abdominal pain, and joint inflammation.
The main treatment approaches for IgA vasculitis include medications, plasma exchange, supportive care, and immunosuppressive therapy. Medications are mainly aimed at reducing inflammation and managing symptoms such as joint pain, skin rash, and kidney issues resulting from immune reactions triggered by IgA deposits. Diagnosis typically involves blood tests, urinalysis, imaging, and tissue biopsy. Treatments are administered via oral, injectable, or intravenous routes and are provided in hospitals, specialty clinics, and homecare settings.
The immunoglobulin A (IgA) vasculitis market research report is one of a series of new reports that provides immunoglobulin A (IgA) vasculitis market statistics, including the immunoglobulin A (IgA) vasculitis industry's global market size, regional shares, competitors with the immunoglobulin A (IgA) vasculitis market share, detailed immunoglobulin A (IgA) vasculitis market segments, market trends and opportunities, and any further data you may need to thrive in the immunoglobulin A (IgA) vasculitis market. This immunoglobulin A (IgA) vasculitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The immunoglobulin A (IgA) vasculitis market consists of revenues earned by entities by providing services such as diagnostic testing, renal function monitoring, patient management programs, and clinical research and trials for novel therapeutics. The market value includes the value of related goods sold by the service provider or included within the service offering. The immunoglobulin A (IgA) vasculitis market also includes sales of corticosteroids, pain relievers, diagnostic kits, and supportive care products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The immunoglobulin A (IgA) vasculitis market size is expected to see strong growth in the next few years. It will grow to $2.08 billion in 2029 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to the increasing use of advanced biomarkers, rising incidence of comorbid conditions, a growing number of clinical trials, heightened interest in biologic therapies, and expanding demand for minimally invasive treatment options. Major trends include the integration of precision medicine, innovations in immunosuppressive therapies, development of disease-modifying treatments, advancements in biomarkers for early diagnosis, and the incorporation of artificial intelligence in treatment planning.
The rising incidence of autoimmune diseases is expected to drive the growth of the immunoglobulin A (IgA) vasculitis market. Autoimmune diseases occur when the immune system mistakenly attacks the body’s own healthy cells, tissues, or organs instead of defending against infections. The increasing prevalence of these disorders is largely attributed to greater exposure to environmental pollutants, which can disrupt immune regulation and trigger abnormal immune responses. IgA vasculitis plays a role in autoimmune diseases by causing inflammation in small blood vessels, providing insights that may aid in understanding and treating various autoimmune conditions. For example, in November 2024, data from Versorgungsatlas.de, a Germany-based organization, reported that out of 73,241,305 insured individuals in 2022, 6,304,340 were diagnosed with at least one autoimmune disease, corresponding to a raw prevalence rate of 8.61%. Therefore, this rising incidence is propelling the growth of the IgA vasculitis market.
The rising focus on targeted therapies is expected to drive the growth of the immunoglobulin A (IgA) vasculitis market. Targeted therapies are treatments designed to specifically inhibit molecular abnormalities involved in diseases, thereby improving treatment precision and minimizing damage to healthy cells. This growing emphasis on targeted therapies is largely fueled by advancements in precision medicine, which tailors treatments based on an individual’s genetic profile for greater effectiveness. In IgA vasculitis, targeted therapies focus on specific immune pathways, reducing systemic side effects, lowering inflammation, and preventing organ damage - ultimately enhancing patient outcomes and quality of life. For example, in December 2024, the American Society of Gene and Cell Therapy (ASGCT) reported that the FDA approved six gene therapy products in 2023, up from five approvals in 2022, reflecting increased innovation in targeted treatments. Therefore, this rising focus on targeted therapies is propelling the immunoglobulin A vasculitis market forward.
Leading companies in the immunoglobulin A (IgA) vasculitis market are concentrating on creating innovative treatments, including targeted biologics and immunomodulators, aimed at lowering inflammation and preventing kidney-related complications. These advanced therapies work by modulating specific immune pathways to decrease inflammation and protect against immune-driven damage in IgA vasculitis. For example, in April 2025, Novartis AG, a pharmaceutical firm based in Switzerland, obtained approval from the U.S. Food and Drug Administration (FDA) for Vanrafia (atrasentan) to treat primary immunoglobulin A nephropathy (IgAN). Vanrafia is a selective endothelin A receptor antagonist taken orally once daily, intended to reduce proteinuria in adults with primary IgAN who face a high risk of rapid disease progression. It can be added to current supportive care plans without requiring a risk evaluation and mitigation strategy (REMS).
Major players in the immunoglobulin A (IgA) vasculitis market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Novartis AG, Takeda Pharmaceutical Company Limited, Amgen Inc., Indraprastha Medical Corporation Limited, Intas Pharmaceuticals Ltd, Mayo Clinic, Biogen Inc., Chugai Pharmaceutical Co. Ltd., The Cleveland Clinic Foundation, Zydus Lifesciences Limited, CSL Behring, Artemis Medicare Services Limited, Biocad Biotechnology Company, Biotest AG, Kauvery Hospitals Private Limited, Sheikh Shakhbout Medical City, and Reliance Life Sciences Pvt. Ltd.
North America was the largest region in the immunoglobulin A (IgA) vasculitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in immunoglobulin A (IgA) vasculitis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the immunoglobulin A (IgA) vasculitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Immunoglobulin A (IgA) vasculitis is an autoimmune disorder marked by inflammation of small blood vessels caused by deposits of IgA antibodies. It primarily affects the skin, joints, kidneys, and gastrointestinal tract, manifesting as purplish rashes, abdominal pain, and joint inflammation.
The main treatment approaches for IgA vasculitis include medications, plasma exchange, supportive care, and immunosuppressive therapy. Medications are mainly aimed at reducing inflammation and managing symptoms such as joint pain, skin rash, and kidney issues resulting from immune reactions triggered by IgA deposits. Diagnosis typically involves blood tests, urinalysis, imaging, and tissue biopsy. Treatments are administered via oral, injectable, or intravenous routes and are provided in hospitals, specialty clinics, and homecare settings.
The immunoglobulin A (IgA) vasculitis market research report is one of a series of new reports that provides immunoglobulin A (IgA) vasculitis market statistics, including the immunoglobulin A (IgA) vasculitis industry's global market size, regional shares, competitors with the immunoglobulin A (IgA) vasculitis market share, detailed immunoglobulin A (IgA) vasculitis market segments, market trends and opportunities, and any further data you may need to thrive in the immunoglobulin A (IgA) vasculitis market. This immunoglobulin A (IgA) vasculitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The immunoglobulin A (IgA) vasculitis market consists of revenues earned by entities by providing services such as diagnostic testing, renal function monitoring, patient management programs, and clinical research and trials for novel therapeutics. The market value includes the value of related goods sold by the service provider or included within the service offering. The immunoglobulin A (IgA) vasculitis market also includes sales of corticosteroids, pain relievers, diagnostic kits, and supportive care products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Immunoglobulin A (IgA) Vasculitis Market Characteristics3. Immunoglobulin A (IgA) Vasculitis Market Trends And Strategies4. Immunoglobulin A (IgA) Vasculitis Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market32. Global Immunoglobulin A (IgA) Vasculitis Market Competitive Benchmarking And Dashboard33. Key Mergers And Acquisitions In The Immunoglobulin A (IgA) Vasculitis Market34. Recent Developments In The Immunoglobulin A (IgA) Vasculitis Market
5. Global Immunoglobulin A (IgA) Vasculitis Growth Analysis And Strategic Analysis Framework
6. Immunoglobulin A (IgA) Vasculitis Market Segmentation
7. Immunoglobulin A (IgA) Vasculitis Market Regional And Country Analysis
8. Asia-Pacific Immunoglobulin A (IgA) Vasculitis Market
9. China Immunoglobulin A (IgA) Vasculitis Market
10. India Immunoglobulin A (IgA) Vasculitis Market
11. Japan Immunoglobulin A (IgA) Vasculitis Market
12. Australia Immunoglobulin A (IgA) Vasculitis Market
13. Indonesia Immunoglobulin A (IgA) Vasculitis Market
14. South Korea Immunoglobulin A (IgA) Vasculitis Market
15. Western Europe Immunoglobulin A (IgA) Vasculitis Market
16. UK Immunoglobulin A (IgA) Vasculitis Market
17. Germany Immunoglobulin A (IgA) Vasculitis Market
18. France Immunoglobulin A (IgA) Vasculitis Market
19. Italy Immunoglobulin A (IgA) Vasculitis Market
20. Spain Immunoglobulin A (IgA) Vasculitis Market
21. Eastern Europe Immunoglobulin A (IgA) Vasculitis Market
22. Russia Immunoglobulin A (IgA) Vasculitis Market
23. North America Immunoglobulin A (IgA) Vasculitis Market
24. USA Immunoglobulin A (IgA) Vasculitis Market
25. Canada Immunoglobulin A (IgA) Vasculitis Market
26. South America Immunoglobulin A (IgA) Vasculitis Market
27. Brazil Immunoglobulin A (IgA) Vasculitis Market
28. Middle East Immunoglobulin A (IgA) Vasculitis Market
29. Africa Immunoglobulin A (IgA) Vasculitis Market
30. Immunoglobulin A (IgA) Vasculitis Market Competitive Landscape And Company Profiles
31. Immunoglobulin A (IgA) Vasculitis Market Other Major And Innovative Companies
35. Immunoglobulin A (IgA) Vasculitis Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Immunoglobulin A IgA Vasculitis Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on immunoglobulin a iga vasculitis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for immunoglobulin a iga vasculitis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The immunoglobulin a iga vasculitis market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Treatment Type: Medications; Plasma Exchange; Supportive Care; Immunosuppressive Therapy2) By Diagnosis Method: Blood Tests; Urinalysis; Imaging Studies; Biopsy
3) By Route Of Administration: Oral; Injectables; Intravenous
4) By End User: Hospitals; Specialty Clinics; Homecare Settings
Subsegments:
1) By Medications: Corticosteroids; Immunosuppressants; Cyclophosphamide; Azathioprine; Mycophenolate Mofetil2) By Plasma Exchange: Therapeutic Plasma Exchange; Plasma Filtration
3) By Supportive Care: Pain Management; Kidney Function Support; Blood Pressure Management
4) By Immunosuppressive Therapy: Methotrexate; Rituximab; Cyclophosphamide
Key Companies Profiled: Pfizer Inc.; F. Hoffmann-La Roche Ltd; Thermo Fisher Scientific Inc.; Novartis AG; Takeda Pharmaceutical Company Limited
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Pfizer Inc.
- F. Hoffmann-La Roche Ltd
- Thermo Fisher Scientific Inc.
- Novartis AG
- Takeda Pharmaceutical Company Limited
- Amgen Inc.
- Indraprastha Medical Corporation Limited
- Intas Pharmaceuticals Ltd
- Mayo Clinic
- Biogen Inc.
- Chugai Pharmaceutical Co. Ltd.
- The Cleveland Clinic Foundation
- Zydus Lifesciences Limited
- CSL Behring
- Artemis Medicare Services Limited
- Biocad Biotechnology Company
- Biotest AG
- Kauvery Hospitals Private Limited
- Sheikh Shakhbout Medical City
- Reliance Life Sciences Pvt. Ltd.